What is Leuprolide?

A 9-amino-acid GnRH analog (Lupron, Eligard) that lowers sex-hormone levels with ongoing use; used in prostate cancer, endometriosis and early puberty.

Leuprolide in the library · · Human Trials · What are peptides?

387 registered trials · 823 indexed papers · 879 human / 9 animal studies

From the PeptideWhiz library entry. "As described" sections summarize claims made in the sources; they are not PeptideWhiz endorsements.

What it is

A 9-amino-acid GnRH analog (Lupron, Eligard) that lowers sex-hormone levels with ongoing use; used in prostate cancer, endometriosis and early puberty.

Type: GnRH analog peptide.

Definition (National Library of Medicine)

“A potent synthetic long-acting agonist of gonadotropin-releasing hormone that regulates the synthesis and release of pituitary gonadotropins, luteinizing hormone and follicle stimulating hormone.”

  • MeSH: Leuprolide

Human research

The registered human trials and peer-reviewed human studies linked below are listed from ClinicalTrials.gov and PubMed. A study is linked only when Leuprolide is one of its interventions, or is named in the study title or subject headings.

Listing a study does not mean it showed a benefit, and it is not medical advice.

Registered human trials (387)

TrialPhaseStatusYearEnrolled
Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate CancerPhase 3recruiting20261500
Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC)Phase 2recruiting2026162
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate CancerPhase 2recruiting202640
Autonomic and Renal Contributions to Hypertension With ADTPhase 4recruiting202650
Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE TrialPhase 2recruiting2026202
Short Course ADT for High Risk Low/Intermediate Risk ARTERA Prostate CancerPhase 2recruiting202690
Neoadjuvant Endocrine Therapy Combined With Chemotherapy in ER-positive, HER2-negative Stage I-III Breast CancerPhase 2not yet recruiting202636
Phase Ia Trial of HHK001 Compared With Enantone in Patients With EndometriosisPhase 1recruiting202630
A Phase Ia Trial Comparing the Pharmacokinetics/Pharmacodynamics, Safety, and Preliminary Efficacy of HHK001 and Enantone in Patients With EndometriosisPhase 1not yet recruiting202620
QL1706 Plus Neoadjuvant Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer With a Poor Response to Neoadjuvant ChemotherapyPhase 2not yet recruiting202640
BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire DisorderPhase 1/Phase 2not yet recruiting2026100
Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CTPhase 2recruiting202650
A Study of Leuprorelin 1-Month (4-Week) Formulation in Children With Central Precocious PubertyPhase 4recruiting202643
Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS TrialPhase 2recruiting202675
Supraphysiologic Testosterone Priming Induces Darolutamide Extended ResponsePhase 2recruiting202660
Rezvilutamide for High-Risk Prostate Cancer After Surgerynot yet recruiting202633
The COSMYC Trial (COmbined Suppression of MYC)Phase 2recruiting202550
Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate CancerPhase 2active not recruiting202525
A Clinical Study of KLH-2109 in Patients With EndometriosisPhase 3active not recruiting2025288
REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac TrialPhase 3recruiting202572
COACTION Trial - COmbination Androgen bloCkade in inTermediate to hIgh-risk prOstate caNcerPhase 4active not recruiting2025144
A Short-term Preoperative, Evaluating Activity and Safety of Elacestrant Monotherapy as Compared to Elacestrant + Ovarian Function Suppression (LHRH Agonist) in Premenopausal Patients With Stage I-II ER+/HER2- Breast CancerPhase 2recruiting2025140
Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate CancerPhase 2withdrawn2025
Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II StudyPhase 2not yet recruiting2025288
Optimal Duration of Hormonal Therapy for Unfavorable Intermediate-risk Prostate Cancer Patients: 6 Versus 12 Months.Phase 3not yet recruiting2025400
Phase IIIb Study of Ribociclib + ET in Early Breast CancerPhase 3recruiting20241444
Efficacy and Safety of DKF-MA102 in Patients With Prostate CancerPhase 3completed2024161
Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate CancerPhase 1active not recruiting20243
RecoverPC: Relugolix vs GnRH Agonist in Quality of LifePhase 2recruiting2024110
Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell TumorsPhase 2active not recruiting202417
Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE TrialPhase 2recruiting2024532
Efficacy and Safety of Leuprolide Acetate [amount hidden] in Subjects With Central Precocious PubertyPhase 4active not recruiting202450
Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate CancerPhase 2recruiting202470
ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate CancerPhase 2recruiting2024392
Safety, Efficacy and Pharmacokinetic Behavior of Leuprolide Injectable Emulsion for Premenopausal Breast Cancer Subjects.Phase 3active not recruiting2024211
Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct CarcinomaPhase 2recruiting202437
Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer PatientsPhase 2recruiting2024124
A Neoadjuvant Study of Abiraterone Acetate, Leuprolide Acetate, and Belzutifan in Men With Regional Prostate CancerPhase 2withdrawn2024
Neo-DAB: Darolutamide and Abemaciclib in Prostate CancerPhase 1terminated20239
Contributions to Hypertension With Androgen Deprivation TherapyPhase 4terminated202310

Peer-reviewed studies (823)

PaperAuthorsJournalYearType
Impact of leuprolide and goserelin on androgen suppression and adverse events in patients with prostate cancerFreitas CSM et al.The Canadian journal of urology2026Randomized Controlled Trial
A phase II study of androgen receptor inhibition by darolutamide in combination with leuprolide acetate and exemestane in recurrent adult-type ovarian granulosa cell tumorHopp EE et al.Gynecologic oncology2026Clinical Trial, Phase II
Linzagolix versus leuprorelin in Japanese women with uterine leiomyomas: a phase 3, randomized, active-controlled, non-inferiority trialOsuga Y et al.Human reproduction (Oxford, England)2026Randomized Controlled Trial
Utility of a 40-minute LH level after depot leuprolide for diagnosis and treatment monitoring in girls with CPPHelvacioglu D et al.Journal of endocrinological investigation2026Randomized Controlled Trial
Fixed Dosing of Leuprolide Acetate, a GnRH Agonist, in Children with Central Precocious Puberty: A Population Pharmacokinetic JustificationLim CN et al.Paediatric drugs2026Randomized Controlled Trial
Apalutamide + Abiraterone Acetate plus Prednisone + Leuprolide with Stereotactic, Ultra-Hypofractionated Radiation in Very High-Risk Prostate Cancer: A Single-Arm, Phase 2 StudyMcBride SM et al.Clinical cancer research : an official journal of the American Association for Cancer Research2026Clinical Trial, Phase II
Coronary Plaque Progression After Androgen Deprivation Therapy in Men With Prostate Cancer: A Randomized Clinical TrialPatel SA et al.JAMA cardiology2026Randomized Controlled Trial
The effectiveness of relugolix compared with leuprorelin for preoperative therapy before laparoscopic myomectomy: a randomized controlled noninferiority study (MyLacR study)Kobori H et al.Fertility and sterility2026Randomized Controlled Trial
Results of the Randomized Phase 3 AFU-GETUG-20 Trial Evaluating Adjuvant Leuprorelin Acetate After Radical Prostatectomy in Men with High-risk Localized Prostate CancerRozet F et al.European urology oncology2026Randomized Controlled Trial
Limosilactobacillus reuteri NCU-37 alleviates leuprorelin-induced perimenopausal syndrome in infertile women by modulating the gut microbiota: a randomized controlled trialWu X et al.Food & function2026Randomized Controlled Trial
Treatment of High-Risk Biochemically Recurrent Prostate Cancer With Enzalutamide in Combination With Leuprolide: Secondary End Points From the EMBARK TrialShore ND et al.The Journal of urology2026Randomized Controlled Trial
Enzalutamide Monotherapy for the Treatment of Prostate Cancer With High-Risk Biochemical Recurrence: EMBARK Secondary End PointsShore ND et al.The Journal of urology2026Randomized Controlled Trial
The effect of the magic glove technique on pain and anxiety in children during leuprolide injection: A quasi-experimental studySadat Hosseini AS et al.Journal of pediatric nursing2026Randomized Controlled Trial
Enzalutamide with or without leuprolide in patients with high-risk biochemically recurrent prostate cancer: EMBARK post hoc analysis by ageShore ND et al.European journal of cancer (Oxford, England : 1990)2026Randomized Controlled Trial
Improved Survival with Enzalutamide in Biochemically Recurrent Prostate CancerShore ND et al.The New England journal of medicine2026Randomized Controlled Trial
Enzalutamide in patients with high-risk biochemically recurrent prostate cancer according to the European Association of Urology definition: a post hoc analysis of EMBARKDe Giorgi U et al.Prostate cancer and prostatic diseases2026Randomized Controlled Trial
Therapeutic impact of leuprorelin acetate on spinal and bulbar muscular atrophy: pre- and post-marketing observational studyHashizume A et al.Journal of neurology2025Observational Study
Prolonged oral GnRH-antagonist administration before euploid embryo transfer in patients with endometriosis: a prospective randomized pilot non-inferiority trialSurrey ES et al.Reproductive biomedicine online2025Clinical Study
A retrospective observational study of changes in uterine fibroid blood flow and fibroid diameter after administration of gonadotropin-releasing hormone agonists and antagonists using superb microvascular imagingTanaka Y et al.The journal of obstetrics and gynaecology research2025Observational Study
Effects of Enzalutamide on the Sexual Activity of Patients with Biochemically Recurrent Prostate Cancer: A Post Hoc Analysis of Patient-reported Outcomes in the EMBARK StudyFreedland SJ et al.European urology2025Randomized Controlled Trial
Unstimulated Luteinizing Hormone for Assessment of Suppression during Treatment of Central Precocious Puberty with 6-Month Subcutaneous Leuprolide Acetate: Correlations with Clinical ResponseKlein K et al.Hormone research in paediatrics2025Clinical Trial, Phase III
The effectiveness of relugolix compared with leuprorelin for preoperative therapy before laparoscopic myomectomy in premenopausal women, diagnosed with uterine fibroids: protocol for a randomized controlled study (MyLacR study)Kitade M et al.Trials2024Clinical Study
Timing of onset of menses after GnRH agonist treatment for central precocious pubertyKlein KO et al.Journal of pediatric endocrinology & metabolism : JPEM2024Clinical Trial
Systemic and Tumor-directed Therapy for Oligorecurrent Metastatic Prostate Cancer (SATURN): Primary Endpoint Results from a Phase 2 Clinical TrialNikitas J et al.European urology2024Clinical Trial, Phase II
Efficacy and Safety of Radiotherapy Plus Relugolix in Men With Localized or Advanced Prostate CancerSpratt DE et al.JAMA oncology2024Randomized Controlled Trial
Efficacy of leuprorelin in spinal and bulbar muscular atrophy: a 3-year observational studyKang MG et al.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2024Observational Study
Postradical prostatectomy prostate-specific antigen outcomes after 6 versus 18 months of perioperative androgen-deprivation therapy in men with localized, unfavorable intermediate-risk or high-risk prostate cancer: Results of part 2 of a randomized phase 2 trialMcKay RR et al.Cancer2024Randomized Controlled Trial
Testosterone Recovery for Relugolix Versus Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO StudyTutrone R et al.European urology oncology2024Randomized Controlled Trial
Enzalutamide and Quality of Life in Biochemically Recurrent Prostate CancerFreedland SJ et al.NEJM evidence2023Randomized Controlled Trial
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate CancerFreedland SJ et al.The New England journal of medicine2023Randomized Controlled Trial

More cited research

Conditions researched

Related compounds

FAQ

What is Leuprolide?

A 9-amino-acid GnRH analog (Lupron, Eligard) that lowers sex-hormone levels with ongoing use; used in prostate cancer, endometriosis and early puberty.

How many registered human trials study Leuprolide?

The PeptideWhiz trial index lists 387 registered trials for Leuprolide, the most recent from 2026.

How much published research exists on Leuprolide?

The PeptideWhiz paper index links 823 PubMed papers to Leuprolide; by study type, 879 human and 9 animal studies.

Which conditions is Leuprolide researched for?

Anti-aging & longevity, Anxiety and panic, Atherosclerosis, cardiovascular disease & high blood pressure, Cognition, focus & brain performance, Dementia, Alzheimer's & cognitive decline, Endometriosis, Fat loss, obesity & body recomposition, Fatigue & low energy (incl. midlife), Female fertility, Gut: IBD (Crohn's, colitis), leaky gut, IBS & ulcers, Immune system (general), Insulin resistance, prediabetes & type 2 diabetes, Kidney protection (CKD, diabetic kidney, lupus kidney), Low testosterone (without or alongside TRT), Lupus (SLE), Male fertility and sperm, Menopause & perimenopause, Menstrual cramps (dysmenorrhea), Migraine, Muscle gain, sarcopenia & building muscle after 40, Osteoporosis and bone density, PCOS, PMDD (premenstrual dysphoric disorder), Post-surgical inflammation and surgery recovery, Pregnancy and breastfeeding: safety notes, Prostate inflammation, Sexual function & libido (women and men), Sleep apnea (obstructive), Sleep problems (incl. insomnia on peptides), Thick blood and blood clots.

Research and education only. Not medical advice. No dosing guidance. Data: ClinicalTrials.gov registry and PubMed via the PeptideWhiz index (204,289 studies).

Reported dosing ranges from research